EPAC1 inhibition protects the heart from doxorubicin-induced toxicity
eLife · 2023
DOI: 10.7554/elife.83831 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Marianne Mazevet und 20 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated, Cardiomyopathies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, LabEx LERMIT, DHU TORINO.
Abstract (Originalsprache)
Anthracyclines, such as doxorubicin (Dox), are widely used chemotherapeutic agents for the treatment of solid tumors and hematologic malignancies. However, they frequently induce cardiotoxicity leading to dilated cardiomyopathy and heart failure. This study sought to investigate the role of the exchange protein directly activated by cAMP (EPAC) in Dox-induced cardiotoxicity and the potential cardioprotective effects of EPAC inhibition. We show that Dox induces DNA damage and cardiomyocyte cell death with apoptotic features. Dox also led to an increase in both cAMP concentration and EPAC1 activity. The pharmacological inhibition of EPAC1 (with CE3F4) but not EPAC2 alleviated the whole Dox-induced pattern of alterations. When administered in vivo , Dox-treated WT mice developed a dilated cardiomyopathy which was totally prevented in EPAC1 knock-out (KO) mice. Moreover, EPAC1 inhibition potentiated Dox-induced cell death in several human cancer cell lines. Thus, EPAC1 inhibition appears as a potential therapeutic strategy to limit Dox-induced cardiomyopathy without interfering with its antitumoral activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France.
- Institut des Maladies Metaboliques et Cardiovasculaires - I2MC, INSERM, Université de Toulouse, Toulouse, France.
- Innovations Thérapeutiques en Hémostase - UMR-S 1140, INSERM, Faculté de Pharmacie, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
- Basic Cardiac Research UCSD School of Medicine La Jolla, San Diego, United States.
- Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France.
- Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France.
ORCID-Profile: Delphine Dayde, Marie-Catherine Vozenin, Rodolphe Fischmeister, Eric Morel
Förderung
- Agence Nationale de la Recherche
- LabEx LERMIT
- DHU TORINO
- Leducq Foundation for Cardiovascular Research
- EU MILEAGE
- Lefoulon Delalande fellowship
Zitieren
APA
Mazevet, M., Belhadef, A., Ribeiro, M., Dayde, D., Llach, A., Laudette, M., Belleville, T., Mateo, P., Gressette, M., Lefebvre, F., Chen, J., Bachelot-Loza, C., Rucker-Martin, C., Lezoualch, F., Crozatier, B., Benitah, J. P., Vozenin, M. C., Fischmeister, R., Gomez, A. M., …, & Morel, E. (2023). EPAC1 inhibition protects the heart from doxorubicin-induced toxicity. eLife. https://doi.org/10.7554/elife.83831
Vancouver
Mazevet M, Belhadef A, Ribeiro M, Dayde D, Llach A, Laudette M, et al. EPAC1 inhibition protects the heart from doxorubicin-induced toxicity. eLife. 2023. doi:10.7554/elife.83831
BibTeX
@article{Mazevet2023,
author = {Mazevet, Marianne and Belhadef, Anissa and Ribeiro, Maxance and Dayde, Delphine and Llach, Anna and Laudette, Marion and Belleville, Tiphaine and Mateo, Philippe and Gressette, Mélanie and Lefebvre, Florence and Chen, Ju and Bachelot-Loza, Christilla and Rucker-Martin, Catherine and Lezoualch, Frank and Crozatier, Bertrand and Benitah, Jean-Pierre and Vozenin, Marie-Catherine and Fischmeister, Rodolphe and Gomez, Ana-Maria and Lemaire, Christophe and Morel, Eric},
title = {EPAC1 inhibition protects the heart from doxorubicin-induced toxicity},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.83831}
}
EUVIMED